Purposeful

 

data finds new uses for existing drugs

What we do

Purposeful is an in silico drug repurposing company that aims to discover alternative uses for existing drugs. We solve the problem of crippling costs associated with drug development by predicting additional effects of compounds already on the market, thus minimizing the number of experiments necessary to carry out before reaching a promising candidate.

Artificial Intelligence

Uncovering novel relationships in chemical and biological data

Data Analytics

Finding signals in structural data using pre- and post-processing methods

Cheminformatics

Extrapolating small molecule mechanism of action

Systems Biology

Omics and pathway data processing

Smart Filtering

Target and disease-specific hierarchy and prioritisation

Phenotype Prediction

Linking gene expression and biological effect

COVID-19

Purposeful joins the fight against COVID-19


Zenodo Research Community

Drug repurposing candidates against COVID-19

Metavallon VC Blog

HealthTech Startups Vs. COVID-19

Mendeley Data

COVID-19: Vaccine, prevention, diagnosis & treatment datasets

Partnerships

Collaborations to date


FRAXA & FRAXA-DVI

Partnership in search of repurposing candidates against Fragile X Syndrome

LEO Pharma: Open Innovation

Partnership on treating rare inflammatory skin disorders

BioEmission Technology Solutions

Partnership on uncovering treatments for rare oncology disorders

Discovery Pipeline

Disease areas under investigation


News

Most recent online mentions of Purposeful


Kathimerini

Greek startups fight back

Greek Investor Guide: Health

Purposeful in the Biology and Technology section of Greek Investor Guide

Greek Investor Guide: Startups

Purposeful in the Startup Stars section of the Greek Investor Guide

Epixeiro

Purposeful the Greek Startup uncovering alternative uses for existing drugs

To Ethnos

Purposeful on the InventICT Incubator

Huffington Post

Purposeful: The Greek Startup searching for cures in rare diseases

To Vima

Greek innovation in Pharmaceutical Research

Metavallon VC

Welcome Purposeful: drug repurposing with a focus on rare diseases

Kathimerini

Talents surfacing through Greek Universities

The Team

Complementary expertise and positive team attitude make us stronger.

Dr. George Drakakis

CEO - Cheminformatics and Drug Discovery

Charalampos Chomenidis

CTO - Software Engineering

 

Dr. Georgia Tsiliki

COO - Statistics and Bioinformatics

Aris Dokoumetzidis

Assistant Professor of Pharmacometrics

 

Contact us

Address

Tritis Septembriou 144, Athens 11251, Greece

E-mail